Project Details
| Short title | FMC-376-CL101 |
|---|---|
| Acronym | PROSPER |
| Status | Active |
| Effective start/end date | 5/09/25 → 7/07/26 |
CTU: An Open-label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
- Parsonson, Andrew (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Quinlan, Gabriel (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- Garcia, Michelle (Clinical Trial Unit Staff)
- Delahunt Smoleniec, Jacqui (Clinical Trial Unit Staff)
- Armstrong, Emilia (Clinical Trial Unit Staff)
- Lawrie, Angus (Clinical Trial Unit Staff)
Project: Research